Mark Levick

Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. Mark’s expertise was gained through a successful career leading global R&D groups at GlaxoSmithKline and Novartis in the UK, US and Switzerland.

At Alvotech, Mark and his team created more than US$1 billion of shareholder value by developing, filing and launching the company’s first commercial product in 17 countries, before taking the company public in June 2022. During this time, the company grew from 350 employees to 1,000 employees; it expanded its active development portfolio, filed its second investigational product, significantly increased its manufacturing and supply chain capacities, gained GMP accreditation in the EU, and extended its global footprint.

In his career, Mark’s has focused value creation on delivering biotech programs for immunological, infectious and inflammatory diseases, resulting in 13 marketing approvals, including five first-in-class molecules and two approvals arising from novel proof-of-concept programs. Mark has expertise in both small molecules and complex biopharmaceuticals, such as engineered proteins, cell-based therapies and novel platforms, especially in the areas of translational medicine, clinical development, technical operations and regulatory affairs.

In addition, Mark is a qualified executive coach who works with senior leaders across different industries and sectors to develop their leadership skills. Mark is also on faculty at Cambridge University where he teaches coaching psychology to postgraduate students.

Before joining industry, Mark was a medical reviewer for the UK and EU medicines regulatory authorities and a specialist physician practicing in hospitals in Australia and the UK. Mark undertook his doctoral studies at Cambridge University as a Commonwealth Scholar, where he was amongst the first researchers to investigate nucleic acid as a novel vaccine platform, which ultimately paved the way for the first approved RNA vaccine for COVID. Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.